Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atherogenics Inc
Original Assignee
The Regents Of The University Of California
Atherogenics, Inc.
Parthasarthy, Sampath
The University Of California
Sampath Parthasarathy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/867,557external-prioritypatent/US5282935A/en
Application filed by The Regents Of The University Of California, Atherogenics, Inc., Parthasarthy, Sampath, The University Of California, Sampath ParthasarathyfiledCriticalThe Regents Of The University Of California
Priority claimed from CA002134679Aexternal-prioritypatent/CA2134679C/fr
Publication of CA2404943A1publicationCriticalpatent/CA2404943A1/fr
Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.
Dérivés de N,N'-di(aralkyl) N,N'-di(Carboxyalkyl) alkylène diamine, et de N-(aralkyl) N'-(carboxyalkyl) N,N'-di(carboxyalkyl) alkylène diamine et de N, N"-di(aralkyl)N,N',N"-tri(carboxyalkyl)dialkylène triamine et utilisation en pharmacie et en cosmétique